Alnylam Pharmaceuticals (ALNY) reported $3.7B in revenue for fiscal 2025, +65.2% year on year. That ranks #973 by revenue among 2853 SEC filers and #85 in Healthcare. Net income was $314M, a net margin of 8.4%. Revenue has grown 62.4% a year on average since 2016 ($47.2M then). The fiscal 2025 balance sheet shows $5.0B in total assets, $1.7B in cash and $676M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $3.7B | +65.2% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $502M | +$678M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $314M | +$592M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $524M | +$532M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $58.7M | +71.2% | FY20252025-12-31 |
| Total assetsAssets | $5.0B | +17.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $789M | +1,076.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $1.7B | +71.5% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $676M | +253.3% | FY20212021-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q2 20262026-06-30 | $1.3B | $164M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 67 of 161 companies compared | 8.4% | |
| Operating marginRank 59 of 160 companies compared | 13.5% | |
| R&D as share of revenueRank 11 of 102 companies compared | 35.5% | |
| Cash as share of revenueRank 12 of 160 companies compared | 44.6% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Alnylam Pharmaceuticals, Inc.
- Ticker
- ALNY
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001178670
Filings
- 10-QJul 30, 2026Open filing →
- 10-QApr 30, 2026Open filing →
- 10-KFeb 12, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Charles River Laboratories InternationalCRL | $4.0B | −$144M |
| Alignment HealthcareALHC | $3.9B | −$724,000 |
| GenmabGMAB | $3.7B | $963M |
| Alnylam PharmaceuticalsALNY | $3.7B | $314M |
| Dentsply SironaXRAY | $3.7B | −$598M |
| Acadia HealthcareACHC | $3.3B | −$1.1B |
| Surgery PartnersSGRY | $3.3B | −$77.9M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Alnylam Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/alnylam-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Alnylam Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/alnylam-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-alnylam-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Alnylam Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/alnylam-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-007497 · February 12, 2026
{{cite web |title=Alnylam Pharmaceuticals — Key figures — 10-K (0001628280-26-007497) |url=https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-12}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.